8 edition of Antiplatelet therapy in ischemic heart disease found in the catalog.
Includes bibliographical references.
|Statement||edited by Stephen D. Wiviott.|
|Series||AHA clinical series|
|Contributions||Wiviott, Stephen D., American Heart Association.|
|LC Classifications||RC685.C6 A69 2009|
|The Physical Object|
|LC Control Number||2008037317|
Editorial from The New England Journal of Medicine — Antiplatelet Therapy for Ischemic Heart Disease. Antiplatelet Therapy for Ischemic Heart Disease; Correction Jul 8, Levine GN, Bates ER, Bittl JA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease.
Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y 12 in hibitor is prescribed in the treatment of acute coronary syndrome (ACS) or following percutaneous coronary intervention (PCI) for drug-eluting stent (DES) important misconception remains that DAPT should be prescribed to prevent stent thrombosis. Although this may seem obvious, it should be . Stable ischemic heart disease, beyond 12 months not well studied. Consider OAC plus aspirin or clopidogrel if high thrombotic risk. • Sarafoff N, Holmes D. Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy.
Ischemic heart disease (IHD) is primarily caused by coronary atherosclerotic plaque formation that leads to an imbalance between ; oxygen supply and demand resulting in myocardial ischemia. Chest pain is the cardinal symptom of myocardial ischemia due to coronary artery disease (CAD). Despite the proven efficacy of current antithrombotic therapy in preventing ischemic heart disease (IHD), vascular events still occur. Our aims were i) to evaluate if combined oral treatment of clopidogrel and LA, a novel nitric oxide donor with anti-ischemic and antiplatelet properties, provides additional antiplatelet effects to those of the blockade of P2Y(12) receptor; and ii) to gain.
Cosmos from Space
first part of the Institutes of the Laws of England
New ICD-9-CM Diagnosis-Related Groups Classification Scheme
What size is it?
theory of the Moiré phenomenon
Europe from the Renaissance to Waterloo (College)
art of mental prayer.
Curiosities of Great Britain.
Sissons Beauties of Sherwood Forest. A guide to the Dukeries and Worksop: with map and copious illustrations
Minerals and metals in ancient India
The character of five selected LANDSAT lineaments in southwestern Pennsylvania. By Noel N. Moebs and Gary P. Sames
Old Saint Pauls
Collins 10,000 French words
This book in the new American Heart Association Clinical Series, explores and explains state-of-the-art use of antiplatelet agents and draws on the expertise of global leaders in antiplatelet ully organized for fast reference, the book is divided into five parts: Concepts in Platelet Physiology, Function, and MeasurementCited by: 1.
This book in the new American Heart Association Clinical Series, explores and explains state-of-the-art use of antiplatelet agents and draws on the expertise of global leaders in antiplatelet ully organized for fast reference, the book is divided into five parts: Concepts in Platelet Physiology, Function, and Measurement.
This book in the new American Heart Association Clinical Series, explores and explains state-of-the-art use of antiplatelet agents and draws on the expertise of global leaders in antiplatelet ully organized for fast reference, the book is divided into five parts: Concepts in Platelet Physiology, Function, and MeasurementPrice: $ Get this from a library.
Antiplatelet therapy in ischemic heart disease. [Stephen D Wiviott; American Heart Association.;] -- This book, part of the American Heart Association Clinical Series, explores and explains state-of-the-art use of antiplatelet agents and draws on the expertise of global leaders in antiplatelet.
This editorial refers to ‘A single-chain antibody-CD39 fusion protein targeting activated platelets protects from cardiac ischaemia/reperfusion injury’ †, by M.
Ziegler et al., on page Platelets play Antiplatelet therapy in ischemic heart disease book major role in the development of ischaemic heart disease. 1 At sites of vascular lesions, platelets adhere to plaque erosions and trigger thrombus formation leading to acute Cited by: 4. The Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Warfarin Substudy examined patients with unstable angina or non–Q wave MI who were randomized to 5 months of therapy with either moderate-intensity anticoagulation with warfarin (INR of 2 to 3) or standard therapy, with a background of initial antiplatelet therapy in.
Diabetes carries a substantial additional ischemic risk for patients with established coronary artery disease despite single antiplatelet therapy with aspirin. 1,2 Recently, two strategies have been evaluated to reverse this high ischemic risk: the addition of an antiplatelet drug, ticagrelor, and the addition of an oral anticoagulant, rivaroxaban.
Secondary Prevention of Coronary Heart Disease and Stroke - Antiplatelet Guideline. The following patients should have antiplatelet therapy for life (unless they develop an indication for anticoagulation): CHD (angina, acute coronary syndrome, post-CABG) Thrombotic stroke or transient ischaemic.
Platelets play an essential role in the pathogenesis of acute coronary syndromes (ACS). 1 Therefore an important part of the treatment of ACS, and of primary and secondary preventive measures in coronary heart disease, consists of antiplatelet treatment. Over the years antiplatelet treatment has evolved, and currently several types of antiplatelet drugs are available, each with their specific.
Abstract. Antiplatelet agents comprise a critical component in the multi-modality treatment of ischemic heart disease. In addition to anticholesterol, beta-blocking, and angiotensin-converting enzyme inhibiting agents as well as mechanical intervention, platelet inhibition has resulted in improved outcomes for patients with ischemic heart by: 1.
Lemesle G, Lamblin N, Meurice T, et al. Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: Prevalence, correlates and impact on prognosis. Am Heart J ; Wiviott SD, Braunwald E, McCabe CH, et al.
Prasugrel versus clopidogrel in patients with acute coronary syndrome. The Problem Antiplatelet therapy is considered a mainstay treatment for the prevention of recurrent cardiovascular events in patients with stable coronary artery disease (CAD). 1 Anticoagulation therapy is consider the cornerstone of therapy for most patients with atrial fibrillation (AF).
AF and CAD are frequent comorbid conditions, occurring in % of patients with stable CAD. Thrombus formation plays a key role in ischemic heart disease. 36 Unstable angina, non–Q wave MI, and ST elevation MI are all caused, in part, by thrombus. Increasingly, it has been appreciated that platelets are a significant component of this thrombus.
62 So-called white thrombus found at sites of arterial injury is rich in platelets. Miller KP, Frishman WH. Platelets and antiplatelet therapy in ischemic heart disease. Med Clin North Am. Jan; 72 (1)– Yusuf S, Wittes J, Friedman L.
Overview of results of randomized clinical trials in heart disease. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.
JAMA. The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention remains a controversial topic. The European Society of Cardiology and the American College of Cardiology/American Heart Association recommend at least 6 and 12 months of DAPT after PCI in patients with stable coronary artery disease or acute coronary syndrome, respectively.
Platelet physiology and the role of the platelet in ischemic heart disease / Robert F. Storey --Laboratory assessment of platelet function and the effects of antiplatelet agents / Alan D.
Michelson, A.L. Frelinger --Cyclooxygenase inhibitors / Nina Chetty Raju, John W. Eikelboom --Aspirin response variability and resistance / Wai-Hong Chen.
The most recent American College of Cardiology/American Heart Association guidelines on duration of dual‐antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug‐eluting stents (DESs) give a class I recommendation to continue DAPT for at least 12 months after an acute coronary syndrome (ACS) and at least 6 months after revascularization in the setting of stable.
Duration of dual anti-platelet therapy: a systematic review for the ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease.
In patients with stable coronary artery disease, long-term single antiplatelet therapy (SAPT) with aspirin reduces the risk of new cardiovascular events by approximately 20–25% compared with placebo.
4,5 Lifelong SAPT with aspirin is therefore recommended as secondary prevention, both in stable coronary artery disease and in stabilized patients >12 months after an acute coronary syndrome.
In book: Antiplatelet Therapy In Ischemic Heart Disease, pp - P = ); this observation could be accounted for by a reduced mortality from ischaemic heart disease.
On-treatment. Duration: 6 months of dual Antiplatelet Therapy (DAPT) Standard duration of DAPT for Stable Ischemic Heart Disease after Drug-eluting Stent (as of ) Duration: 12 months of dual Antiplatelet Therapy (DAPT) Acute Coronary Syndrome event (regardless of stenting) Duration: 18 months of dual Antiplatelet Therapy (DAPT).Stroke is a leading cause of mortality and disability worldwide.
1 Initial manifestations of acute cerebral ischemia, such as ischemic stroke and transient ischemic attack (TIA), are often followed by recurrent vascular events, including recurrent stroke.
2 To reduce this burden, antiplatelet therapy is a key component of the management of noncardioembolic ischemic stroke and TIA. 3 This. Antiplatelet therapy is used for both the management of acute ischemic stroke and for the prevention of stroke. Antiplatelet therapy reduces the incidence of stroke in patients at high risk for atherosclerosis and in those with known symptomatic cerebrovascular disease.
Antiplatelet therapy for secondary stroke prevention will be reviewed here.